Allergen Delivery Inhibitors: Preclinical evaluation Allergen DeliveryInhibitors offer the potential to combine alleviation of asthma with allergy prophylaxis using small molecule inhaled therapy. (360G-Wellcome-081514_A_06_B)
Researchers at St George’s, University of London and the University of Manchester have employed structure-based drug design to develop inhibitors that selectively target house dust mite cysteine peptidases, enzymes that make significant contributions to the development, maintenance and escalation of allergic diseases including asthma. The programme’s candidate drug (CD 1) displays in vivo efficacy in animal models with a good duration of action when delivered to the airways. CD 1 is supported by several developable back-up compounds from chemically distinct and mechanistically distinct series. A patent portfolio is being created and Technology Transfer is seeking a development and commercialisation partner for this programme.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Amount Awarded | 67925 |
| Applicant Surname | Robinson |
| Approval Committee | Seeding Drug Discovery Committee |
| Award Date | 2007-12-19T00:00:00+00:00 |
| Financial Year | 2007/08 |
| Grant Programme: Title | Seeding Drug Discovery Award |
| Internal ID | 081514/A/06/B |
| Lead Applicant | Dr Clive Robinson |
| Other Applicant(s) | Prof David Garrod |
| Partnership Value | 67925 |
| Planned Dates: End Date | 2008-04-03T00:00:00+00:00 |
| Planned Dates: Start Date | 2007-06-04T00:00:00+00:00 |
| Recipient Org: Country | United Kingdom |
| Region | Greater London |